Inhibitory effect of 2,3-butanedione monoxime (BDM) on Na(+)/Ca(2+) exchange current in guinea-pig cardiac ventricular myocytes.
1. The effect of 2,3-butanedione monoxime (BDM), a 'chemical phosphatase', on Na(+)/Ca(2+) exchange current (I(NCX)) was investigated using the whole-cell voltage-clamp technique in single guinea-pig cardiac ventricular myocytes and in CCL39 fibroblast cells expressing canine NCX1. 2. I(NCX) was identified as a current sensitive to KB-R7943, a relatively selective NCX inhibitor, at 140 mM Na(+) and 2 mM Ca(2+) in the external solution and 20 mM Na(+) and 433 nM free Ca(2+) in the pipette solution. 3. In guinea-pig ventricular cells, BDM inhibited I(NCX) in a concentration-dependent manner. The IC(50) value was 2.4 mM with a Hill coefficients of 1. The average time for 50% inhibition by 10 mM BDM was 124+/-31 s (n=5). 4. The effect of BDM was not affected by 1 microM okadaic acid in the pipette solution, indicating that the inhibition was not via activation of okadaic acid-sensitive protein phosphatases. 5. Intracellular trypsin treatment via the pipette solution significantly suppressed the inhibitory effect of BDM, implicating an intracellular site of action of BDM. 6. PAM (pralidoxime), another oxime compound, also inhibited I(NCX) in a manner similar to BDM. 7. Isoprenaline at 50 microM and phorbol 12-myristate 13-acetate (PMA) at 8 microM did not reverse the inhibition of I(NCX) by BDM. 8. BDM inhibited I(NCX) in CCL39 cells expressing NCX1 and in its mutant in which its three major phosphorylatable serine residues were replaced with alanines. 9. We conclude that BDM inhibits I(NCX) but the mechanism of inhibition is not by dephosphorylation of the Na(+)/Ca(2+) exchanger as a 'chemical phosphatase'.
Watanabe
Y
Y
Department of Ecology and Clinical Therapeutics, School of Nursing, Fukushima Medical University, Fukushima 960-1295, Japan.
Iwamoto
T
T
Matsuoka
I
I
Ohkubo
S
S
Ono
T
T
Watano
T
T
Shigekawa
M
M
Kimura
J
J
D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D002478:Cells, Cultured; D002801:Cholinesterase Reactivators / Q000494:pharmacology; D003931:Diacetyl / Q000031:analogs & derivatives / Q000494:pharmacology*; D004347:Drug Interactions; D004594:Electrophysiology; D015870:Gene Expression / Q000187:drug effects; D006168:Guinea Pigs; D006352:Heart Ventricles / Q000187:drug effects; D006868:Hydrolysis; D007545:Isoproterenol / Q000494:pharmacology; D009206:Myocardium / Q000378:metabolism*; D019319:Okadaic Acid / Q000494:pharmacology; D018408:Patch-Clamp Techniques; D011220:Pralidoxime Compounds / Q000494:pharmacology; D019831:Sodium-Calcium Exchanger / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000502:physiology; D014357:Trypsin / Q000494:pharmacology; D016276:Ventricular Function
D002801:Cholinesterase Reactivators; D011220:Pralidoxime Compounds; D019831:Sodium-Calcium Exchanger; C110374:sodium-calcium exchanger 1; C004717:diacetylmonoxime; D019319:Okadaic Acid; D000255:Adenosine Triphosphate; D014357:Trypsin; D003931:Diacetyl; D007545:Isoproterenol; C028797:pralidoxime